These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26679394)

  • 21. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
    Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.
    Santagostino E; Lentz SR; Busk AK; Regnault A; Iorio A
    Haemophilia; 2014 Jul; 20(4):527-34. PubMed ID: 24471912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
    Pocoski J; Li N; Ayyagari R; Church N; Maas Enriquez M; Xiang Q; Kelkar S; Du EX; Wu EQ; Xie J
    J Blood Med; 2016; 7():129-37. PubMed ID: 27445511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
    Boban A; Hermans C
    Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
    [No Abstract]   [Full Text] [Related]  

  • 25. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.
    John MJ; Chakrabarti P; Apte S; Bhattacharyya M; S C; Hansen T; Kolla R; Ross C; Seth T; Siddharthan N; Abraham A
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1324-1330. PubMed ID: 33313471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
    Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune tolerance induction rescue with turoctocog-alfa in a poor risk haemophilia A inhibitor young child: the history of a success.
    Zanon E; Milan M; Pasca S
    Blood Coagul Fibrinolysis; 2018 Jul; 29(5):465-468. PubMed ID: 29652676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new recombinant factor VIII: from genetics to clinical use.
    Santagostino E
    Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
    Ezban M; Vad K; Kjalke M
    Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
    Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
    Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT; Scott LJ
    Drugs; 2017 Oct; 77(15):1677-1686. PubMed ID: 28900904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Damoctocog Alfa Pegol: A Review in Haemophilia A.
    Paik J; Deeks ED
    Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
    Johansen PB; Tranholm M; Haaning J; Knudsen T
    Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
    Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
    Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
    Matsushita T; Mangles S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.